Facebook Pixel India approves Research Development and Innovation scheme with corpus of Rs 1 lakh cr | BioSpectrum Asia - business - Magzter.comでこの記事を読む

試す - 無料

India approves Research Development and Innovation scheme with corpus of Rs 1 lakh cr

BioSpectrum Asia

|

BioSpectrum Asia August 2025

In a transformative step to bolster India's research and innovation ecosystem, the Union Cabinet, chaired by Prime Minister Narendra Modi, has approved the Research Development and Innovation (RDI) Scheme with a corpus of Rs one lakh crore.

India approves Research Development and Innovation scheme with corpus of Rs 1 lakh cr

Recognising the critical role that the private sector plays in driving innovation and commercialising research, the RDI Scheme aims to provide long-term financing or refinancing with long tenors at low or nil interest rates to spur private sector investment in RDI. The scheme has

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

India Health Fund supports D-Nome to bolster molecular TB screening in India

India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform

BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan

Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

Listen

Translate

Share

-
+

Change font size